⚡️ New multicenter data on SBRT for primary renal cell carcinoma (RCC): - 98% LC at 1 year, 96% at 5 years - Median OS: 58 months - Preserved renal function & low severe toxicity A promising noninvasive option for inoperable RCC #KidneyCancer #Oncology Shankar Siva

Development and Validation of an Artificial Intelligence Digital Pathology Biomarker to Predict Benefit of Long-Term Hormonal Therapy and Radiotherapy in Men With High-Risk Prostate Cancer Across Multiple Phase III Trials ascopubs.org/doi/abs/10.120…

Delighted to have contributed on prostate cancer! Very nice work, thank you all. Congratulations Arnaud BEDDOK and all

This is a major story from #ASCO25. Randomized phase 3 trial of time of day of immunotherapy infusion. Randomized to infusion before or after 3pm. Early infusion far superior: PFS 11.3 vs 5.7 HR 0.42, OS HR 0.45! Impactful, pragmatic, not costly. This should be a bigger story.

⚠️ The missing subplot in #KEYNOTE689 🧠💉 Yes, periop #pembrolizumab improved EFS in resectable LA-HNSCC. But what about crossover? 🧩 Not allowed. 📉 Post-progression therapy not reported. In a post–#KEYNOTE048 world, that’s a problem. 💣 Why it matters: No ICI for progressing

Brief 🧵 1/ How common is *failure* of modern active surveillance (AS) for #ProstateCancer (PCa)? Which patients are at higher risk? Spoiler 🚨: it’s pretty simple European Urology Oncology @UroToday OncoAlert PCF Science GU Cast | Urology podcast! Amer. Urol. Assn. European Association of Urology (EAU)

In a population-based cohort in Sweden, the 10-yr risk of PSA persistence or relapse after radical prostatectomy was 34%. Adverse pathology, PSA persistence, and early relapse independently predict higher prostate cancer mortality. oxford.ly/44zedf0

Delighted to have contributed! Huge and comprehensive work

🔥 RTOG 9601 – Long-Term Data Just Dropped! OncoAlert 📌 Salvage RT with vs. without Anti-Androgen Therapy (AAT) in men with post-prostatectomy recurrence (PSA 0.2–4.0, pT2/3N0) 💊 24 months of bicalutamide 150 mg during & after RT 🎯 18-Year Outcomes (n=760): • 🧬 Overall

Did you get the email I sent?

Intéressé par une comparaison des logiciels de contourage automatique des #CancerDuSein & #CancerDeLaProstate dans les centres de #radiothérapie des Hauts de France ? Venez lire le poster PO03_018 du Prof. David Pasquier (Centre Oscar Lambret) #CongresSFRO2025 #RadOnc @sfro_fr

An intriguing poster at #ASTRO25 demonstrates that major North American TV Shows are leading viewers to believe radiation might cause "internal melting, burning, or crumbling, or even a food allergy". ASTRO Jeff White Neha Vapiwala Sue Yom poster.astro.org/astro/2025/67t…

James Yu #GU005 SBRT had better QOL vs MHF (20-28fx) in: 1 year: sexual and bowel 2 years: urinary irritation Spacers / balloons didn't influence outcomes

SBRT vs IMRT for #ProstateCancer PACE-B: high SBRT dose ➡️ slightly higher tox. Great onc outcomes GU005: low SBRT dose ➡️ slightly lower tox. Slightly worse BCR RadTARGET: asking a good Q! Focal boost w de-intensification of normal prostate. NCT06990542 #ASTRO25 UC San Diego Health Moores Cancer Center